Singapore markets close in 4 hours 12 minutes
Straits Times Index
3,205.65 -12.52 (-0.39%) Nikkei
28,821.51 -276.73 (-0.95%) Hang Seng
25,604.81 -23.93 (-0.09%) FTSE 100
7,253.27 -24.35 (-0.33%) BTC-USD
58,874.96 -2,510.41 (-4.09%) CMC Crypto 200
1,411.78 -62.55 (-4.24%)
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
66.77-0.96 (-1.42%)
At close: 4:00PM EDT
| Previous close | 67.73 |
| Open | 67.96 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 1200 |
| Day's range | 66.60 - 67.96 |
| 52-week range | 56.56 - 73.34 |
| Volume | 4,887,086 |
| Avg. volume | 6,233,656 |
| Market cap | 83.717B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 16.35 |
| EPS (TTM) | 4.09 |
| Earnings date | 28 Oct 2021 |
| Forward dividend & yield | 2.84 (4.19%) |
| Ex-dividend date | 14 Sep 2021 |
| 1y target est | 76.26 |
- Zacks
Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More
Earnings and other updates from bigwigs like Bristol Myers (BMY) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.
- Zacks
Healthcare ETFs in Focus as Q3 Earnings Unfold
The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.
- Motley Fool
2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays
With that in mind, let's look at two healthcare stocks that have performed poorly over the past year but have a chance to bounce back big: Gilead Sciences (NASDAQ: GILD) and Incyte (NASDAQ: INCY). Biotech giant Gilead Sciences is still feeling the aftereffects of a regulatory setback related to filgotinib, its potential medicine for rheumatoid arthritis. The company hoped that it would become a blockbuster product, but the U.S. Food and Drug Administration (FDA) had other plans.
© 2021 Verizon Media. All rights reserved.
